These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 7682357)
1. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir. Nakazato PZ; Burns W; Moore P; Garcia-Kennedy R; Cox K; Esquivel C Transplant Proc; 1993 Apr; 25(2):1935-7. PubMed ID: 7682357 [No Abstract] [Full Text] [Related]
2. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
3. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
5. Incidence and therapy of cytomegalovirus disease after liver transplantation. Wiens M; Lefèbre B; Blumhardt G; Schmidt CA; Lohmann R; Neuhaus P Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829 [No Abstract] [Full Text] [Related]
16. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972 [No Abstract] [Full Text] [Related]
17. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir. Prian GW; Koep LJ Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977 [No Abstract] [Full Text] [Related]
18. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]
19. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis. Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175 [TBL] [Abstract][Full Text] [Related]